Prothena

PRTANASDAQ

Antibody therapeutics targeting misfolded proteins

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-10-02. Published by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

text updated 2026-10-02 · archived: kept for reference, not maintained · where each field comes from

protein misfolding diseasesneurodegeneration

Key figures from SEC filings

We have not parsed a 10-Q or 10-K for PRTA yet, so this page shows no cash, burn or runway figure rather than an estimate. Revenue stage: Pre-revenue.

Upcoming catalysts

No upcoming catalyst for Prothena has been confirmed against a primary source. Rather than estimate one, this section is left empty — check the company's investor relations page and ClinicalTrials.gov directly.

Pipeline

DrugIndicationPhaseExpected data
BirtamimabAL amyloidosisPhase 3StoppedStudy stopped — registry▼
PRX012Alzheimer diseasePhase 1Not disclosed▼
PRX005tauopathiesPhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Prothena that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade PRTA commission-free on Webullvia Webull · Affiliate

Comparable companies

Denali TherapeuticsBiogenAC Immune

Sponsored

Get premium PRTA analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Prothena has 6 Phase 2 or 3 studies on ClinicalTrials.gov: 2 completed, 4 stopped early.

2

Completed

4

Stopped early

0

Ongoing

Stopped early

  • AFFIRM-ALPhase 3 · started 2021 · terminated

    Birtamimab in light chain (al) amyloidosis · n=208

    Reason given: The AFFIRM-AL clinical trial did not meet its primary endpoint.

  • NCT03154047Phase 2 · started 2017 · terminated

    NEOD001 in al amyloidosis · n=80

    Reason given: NEOD001 program terminated due to lack of clinical benefit

  • OLEPhase 2 · started 2016 · terminated

    NEOD001 in al amyloidosis · n=34

    Reason given: NEOD001 program terminated due to lack of clinical benefit

  • VITALPhase 3 · started 2015 · terminated

    NEOD001 in primary systemic (al) amyloidosis · n=260

    Reason given: The VITAL study was terminated due to futility analysis

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.